Vadodara January 22nd, 2019
Alembic Pharmaceuticals Limited reported its financial results for the third quarter ending 31st December 2018.
Financial Highlights – Consolidated
· Net Sales for the quarter up 21% to Rs 1018 crores from Rs. 840 crores.
· Net Profit for the quarter up 25% to Rs 162 crores
· Net sales for FY19 up 32% to Rs 3008 crores against Rs 2277 crores last year.
· Net profit for FY19 up 47% to Rs 467 crores from Rs 317 Crores last year.
Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “The growth in the quarter was attributed to a strong performance in the US and International business. Our Formulation as well as API Facilities were successfully approved by the US FDA during the quarter”.
Operational Highlights for the quarter
International Business
· International Formulations grew 44% to Rs 448 crores for the quarter.
· The US business grew by 42% to Rs 308 crores for the quarter
· 7 ANDA approvals received during the quarter, 83 Cumulative ANDA approvals.
· 3 new products launched in the US market.
· 4 ANDA filings during the quarter, Cumulative ANDA filings at 147.
· R&D spend at Rs 112 Crores for the quarter, 11% of Sales.
India Formulations Business
· India formulations business for the quarter grew by 4% to Rs 365 crores as against Rs. 349 crores last year.
API Business
· API Business for the quarter grew by 14% to Rs 205 Crores as against Rs 180 Crores last year.
Summary of Total Revenue is as under:
(Rs in Crores)
Particulars
|
Q3 FY19
|
Q3 FY18
|
% Change
|
9M FY19
|
9M FY18
|
% Change
|
Formulation
|
||||||
USA
ROW
|
308
140
|
218
93
|
42%
50%
|
945
442
|
605
249
|
56%
77%
|
India
|
365
|
349
|
4%
|
1080
|
970
|
11%
|
API
|
205
|
180
|
14%
|
540
|
453
|
19%
|
Total
|
1018
|
840
|
21%
|
3008
|
2277
|
32%
|
The Profit break-up is as under:
(Rs in Crores)
Particulars
|
Q3 FY19
|
Q3 FY18
|
% Change
|
9M FY19
|
9M FY18
|
% Change
|
EBITDA Pre R&D
|
351
|
281
|
25%
|
1061
|
755
|
41%
|
EBITDA Pre R&D %
|
34%
|
34%
|
35%
|
33%
|
||
EBITDA Post R&D
|
245
|
188
|
31%
|
701
|
477
|
47%
|
EBITDA Post R&D %
|
24%
|
22%
|
23%
|
21%
|
||
Profit Before Tax
|
211
|
161
|
31%
|
603
|
400
|
51%
|
Net Profit after Tax
|
162
|
130
|
25%
|
467
|
317
|
47%
|
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic’s brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.
Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)
For more information contact:
Ajay Kumar Desai
Phone: +91 22 – 306 11681
|
Mitanshu Shah
Phone: +91 265 – 3007630
|
For more information Contact
Maulikk Buch
Chief Publicist
REOPINION
99783389999
22.307158873.1812187